Epizyme, Inc.

Glaxosmithkline Intellectual Property Development Limited

Elayne Penebre

Kenneth William Duncan

Richard Chesworth

Michael John Munchhof

John Emmerson Campbell

Lei Jin

Paula Ann Boriack-Sjodin

Christine Klaus

Maria Alejandra Raimondi

Olena I Barbash

The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.

Combination therapies with EHMT2 inhibitors

Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.

PRMT5 inhibitors and uses thereof

Growing community of inventors

Auburndale, MA, United States of America

Elayne Penebre